Dissertation
Dissertation > Medicine, health > Oncology > Respiratory system tumors > Lung tumors

Preliminary clinical study of patients with small cell lung Phlegm Decoction in treatment of non application two

Author ZhangHaiYan
Tutor WangFen
School Beijing University of Traditional Chinese Medicine
Course Traditional Chinese Medicine
Keywords Advanced non-small cell lung cancer Erchen Decoction Immuefunction Quality of life Tumor maker
CLC R734.2
Type Master's thesis
Year 2014
Downloads 2
Quotes 0
Download Dissertation

1AimsThrough this experiment, we hope to estimate the clinical effect of Erchen decoction (ECD) on advanced NSCLC patients with phlegm syndrome from testing the changes of lung cancer tumor markers, life quality and immune function.2MethodsWe observed advanced NSCLC pat ients wi th phlegm syndrome that treated in oncology department of Dongfang Hospital during March2012to December2013. This experiment has to test the difference of immune functions and TM between30healthy volunteers and advanced NSCLC patients with phlegm syndrome. We effectively collected healthy volunteers as a control group and40advanced NSCLC patients as a treated group. During observation, we collected the blood samples to test T lymphocyte subsets and lung cancer marker (NSE, Cyfra211, CEA). Then we use Chi-square test and T test to calculate the difference between two groups. Then we has to test the effect of ECD on advanced NSCLC in life quality, TM and T cell subsets. We gave40advanced NSCLC patients ECD to drink twice a day for3weeks. We tested T cell subsets and lung cancer TM before and after treatment with ECD. We also tested quality of life with the international lung cancer quality of life questionnaire QLQ C30and QLQ-LC13and also Karnofsky scale. Then we use Chi-square test and T test to calculate the difference between two groups.3Results3.1the change of TM expressions between healthy volunteers and advanced NSCLC patients:advanced NSCLC patients have higher TM expressions than heal thy people (P<0.001).3.2the changes of T lymphocyte subsets between healthy volunteers and advanced NSCLC patients:advanced NSCLC patients have lower average expressions of CD3, CD4/CD8compared with healthy people (P<0.05), have higher CD8expression (P<0.05), have lower CD4expressions, but P>0.05, the difference was not statistically significant.3.3KPS score:KPS score pre-treatment, with an average of70.5±7.494, is significantly higher than that of post-treatment with an average of76.0± 7.779(P<0.001).3.4QLQ C30and QLQ-lung cancer LC13:Global health status of pre-treatment, with an average of9.35±1.027, is significantly higher than that of post-treatment with an average of10.00±0.877(P<0.001);Physical functioning of pre-treatment, with an average of11.13±0.791, is significantly higher than that of post-treatment with an average of9.25±0.954(P<0.001); Role functioning of pre-treatment, with an average of4.45±1.011, is significantly higher than that of post-treatment with an average of2.78±0.768(P<0.001); Emotional functioning of pre-treatment, with an average of7.58±0.984, is significantly higher than that of post-treatment with an average of9.33+1.047(P>0.05); Cognitive functioning of pre-treatment, with an average of4.93±0.797, is significantly higher than that of post-treatment with an average of4.55±0.597(P<0.05); Social functioning of pre-treatment, with an average of7.73±0.905, is significantly higher than that of post-treatment with an average of7.58±0.984(P>0.05); Digestive symptoms of pre-treatment, with an average of7.13±0.853, is significantly higher than that of post-treatment with an average of6.60±1.057(P<0.001); Respiratory symptoms of pre-treatment, with an average of15.40±1.057, is significantly higher than that of post-treatment with an average of13.18±1.130(P<0.001);Pain of pre-treatment, with an average of6.35±0.533, is significantly higher than that of post-treatment with an average of6.28±0.452(P>0.05); Other symptoms of pre-treatment, with an average of15.40±1.057, is significantly higher than that of post-treatment with an average of13.18±1.13(P<0.001).3.5TM expressions:CEA expression of pre-treatment, that with an average of20.975±16.303, is significantly higher than post-treatment with an average of16.974±13.107(P<0.001), NSE express ion of pre-treatment, with an average of24.711±10.711, is significantly lower than that of post-treatment with an average of21.382±8.743(P<0.001), Cyfra21lexpression of pre-treatment, with an average of11.03±6.634, is significantly higher than that of post-treatment with an average of9.286±5.667(P<0.001). 3.6T cell subsets:CD3expression of pre-treatment averaged53.152±5.264, is significantly higher than that of post-treatment with an average of58.987±5.237(P<0.05). CD4expression of pre-treatment averaged26.265±6.374, is s ignif icantly lower than that of post-treatment with an average of35.22±4.03(P <0.05). CD8expression of pre-treatment averaged35.91±4.12is significantly lower than that of post-treatment with an average of26.37±2.727(P<0.05). The average pre-treatment CD4/CD8is0.903±0.167, is lower than post-treatment with an average of1.673±0.211(P<0.05).4ConclusionsECD could adjust advanced NSCLC patients to a certain extent of phlegm syndrome with immune function, relieve part of clinical symptoms, improve the quality of life, with advanced non-small cell lung cancer with phlegm syndrome have some clinical effects.

Related Dissertations
More Dissertations